$PFE

BioNTech sues Moderna for patent infringement over next-gen COVID vaccine technology, claiming mNEXSPIKE violates its spike protein patents. Seeking damages for unlicensed use.

GLP-1 therapeutics market projected to grow from $22B in 2025 to $33B by 2030, driven by formulation innovations like oral and extended-release therapies improving accessibility.

Sexual health supplement market projected to grow 40% to $5.31 billion by 2030, driven by consumer wellness awareness and demand for natural, personalized products.

Turner Syndrome treatment market projected to double to $3.67B by 2033, driven by diagnostic innovation, increased awareness, and improved access to therapies globally.

Pfizer's Braftovi regimen met primary endpoints in Phase 3 colorectal cancer trial, showing significant improvements in progression-free survival versus standard chemotherapy in BRAF-mutated patients.

Fibrin sealant market to double from $1.60B to $3.57B by 2035, driven by surgical demand and minimally invasive techniques despite accessibility challenges in developing regions.

Global uterine fibroid treatment market projected to grow 7.63% annually through 2033, reaching $9.43 billion. Growth driven by high disease prevalence and minimally invasive surgical advances.

Eli Lilly strengthens market position through GLP-1 dominance and strategic acquisitions like Orna Therapeutics, diversifying growth beyond patent cliff risks.

Pfizer's 6.3% dividend yield depends on GLP-1 drug success and managing upcoming patent cliffs as it competes against rivals Novo Nordisk and Eli Lilly in obesity treatments.